Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
about
Chemotherapy for hormone-refractory prostate cancerBisphosphonates for advanced prostate cancerFrom palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastasesTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerA systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortalityPatient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastasesEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerNovel non-AR therapeutic targets in castrate resistant prostate cancerFinal quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).Future of bisphosphonates and denosumab for men with advanced prostate cancer.Bone health and prostate cancer.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerPreventing bone complications in advanced prostate cancerRecommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic reviewQuality of life measurement in bone metastases: A literature review.Treatment and prevention of bone complications from prostate cancer.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisNCCN Task Force Report: Bone Health in Cancer Care.Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Contemporary therapeutic approaches targeting bone complications in prostate cancerA multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Bisphosphonate therapy in the oncology setting.Is there a role for chemotherapy in prostate cancer?Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion.The role of bisphosphonates in the treatment of prostate cancer.Bisphosphonates and bone metastases: current status and future directions.New therapeutic agents for the treatment of bone diseases.Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.Current approaches to bone-targeted therapy in genitourinary malignanciesBiphosphonates in advanced prostate and renal cell cancer--current status and potential applications.A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancerThe use of bisphosphonates in cancer patients.New and emerging therapies for bone metastases in genitourinary cancers.Emerging therapies to prevent skeletal morbidity in men with prostate cancer.Cervical actinomycosis with spinal cord compression. Case report and literature review.
P2860
Q24243797-44E4493C-A2C5-4132-B41C-E804347B3444Q24244161-26E4311A-693C-41E4-89B2-C0D67078A6D0Q26740064-EFF94D5E-B2BE-4390-A336-D2B7B29CF6E0Q26752785-7374B075-F2C8-45E6-A2FD-C0A0DD519A9BQ26782066-C14165A1-1EF7-4592-876B-AB02FCCF46BBQ26997330-0F85390A-2087-46CA-A247-DB4A4287F3CBQ27010542-E72A23C7-9BC9-4F97-A562-F10DBD85D664Q27021268-3E06448B-4548-4C04-8213-B55EBEABCBF7Q28383663-FCA906E1-4A6F-46C1-90BF-D54A813C7740Q30886900-965D1647-C3D6-41AB-9CB9-226BC4EC6E23Q33583525-24E6163D-6E8D-4C3C-9917-3541C9FF774FQ33977536-77BD3863-8DF6-4948-9304-A32FD6AA4512Q34023510-4C89E9A4-39B1-4AF8-B6F4-263D70C950C0Q34111634-69DF3F18-82F6-4D86-B47A-6098BD4AECF9Q34315605-43F42494-CEB8-463C-8947-3B12D7438009Q34320376-8C8D910B-C9C1-459D-A4D7-6D74D8EEA7BEQ34367585-35992DD7-E568-42DC-B9EA-772311BB5313Q34418172-A97ADAA9-2FBB-4869-97E2-90562758A7F3Q34441944-52CAFAF4-EB7A-493F-9D29-9E8A2BD56F34Q34448130-2A89D317-E4E5-46D3-A842-532E83861B5BQ34617936-E0AEB2F3-AE76-49BA-BF68-0E08405AE3F1Q34960635-A343BCE9-1355-4466-8A3A-377575524460Q34960778-2428EBA0-0D85-440F-BACD-0C753E09CE88Q35018896-DA183EA3-7A88-4353-93D5-F3989C8E6FFCQ35087364-FE702EB9-44C9-4990-91A5-67E684A826C4Q35602668-AE89570F-C62F-45B2-B33D-E9478077C7B4Q35776921-066FD73E-4BEC-40D2-AD7D-9D2DAF6A0D89Q35865726-6C6CE378-CDD9-400C-931C-02F5A62ADF5DQ35942134-645694F4-1F6C-4076-9750-F4C52CD34649Q36102276-F70C9DB8-6C0E-4D3E-A698-7D4E29950583Q36118409-9DF6854D-B02B-4B66-8829-BB07B3A89F32Q36161232-91CFF907-CB33-443C-96CB-8803CDD741E2Q36217148-DDD78623-43CE-470E-ABF2-409C6DF7547FQ36231718-898C95F7-90F5-42BF-A2AF-97CD544FD6F0Q36403183-5CF2123C-D594-4256-BFE0-AB99E2CC740DQ36553038-5B32EF6A-1830-426B-907C-857EC670E809Q36846894-A07D57FD-8B9F-442C-9852-8196A685429FQ36866291-BA266079-243C-4F45-86AB-1A29CFF18D79Q36910469-0E7EBD30-6DD0-41A7-9B21-4B570206F45EQ37029680-74B4979F-B601-4041-AD71-091EAE1EABF5
P2860
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@en
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@nl
type
label
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@en
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@nl
prefLabel
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@en
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@nl
P2093
P356
P1476
Randomized, double-blind, cont ...... tory prostate cancer and pain.
@en
P2093
Parulekar W
Tannock IF
Winquist EW
P304
P356
10.1200/JCO.2003.03.042
P407
P577
2003-09-01T00:00:00Z